Medinno
Seoul
About Medinno
Medinno develops cell therapeutics for brain diseases. The company's therapy uses technology to treat a wide range of diseases, including hypoxic-ischemic encephalopathy, neonatal refractory brain diseases, and severe intraventricular hemorrhages..
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Total funding: $8.2M
- Funding stage: Late Stage Venture
- Last round: Series C (Oct 2023)
- Website: medinno.kr
- Phone: 02-6925-2860
Industries & Categories
Biotechnology, Health Care, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/medinno-56999 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.